Clinical Trial Update: Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 study of a modified recombinant Factor VIII (OBI-1) in acquired Hemophilia A has completed with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Hemophilia

Drugs mentioned

• OBI-1 (modified recombinant Factor VIII)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Acquired Hemophilia A | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2015-12-21